<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39422261</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>18</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>23</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2164-554X</ISSN><JournalIssue CitedMedium="Internet"><Volume>20</Volume><Issue>1</Issue><PubDate><Year>2024</Year><Month>Dec</Month><Day>31</Day></PubDate></JournalIssue><Title>Human vaccines &amp; immunotherapeutics</Title><ISOAbbreviation>Hum Vaccin Immunother</ISOAbbreviation></Journal><ArticleTitle>Safety and immunogenicity of a modified mRNA-lipid nanoparticle vaccine candidate against COVID-19: Results from a phase 1, dose-escalation study.</ArticleTitle><Pagination><StartPage>2408863</StartPage><MedlinePgn>2408863</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">2408863</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1080/21645515.2024.2408863</ELocationID><Abstract><AbstractText>This phase 1, open-label, dose-escalation, multi-center study (NCT05477186) assessed the safety and immunogenicity of a booster dose of an mRNA COVID-19 vaccine (CV0501) encoding the SARS-CoV-2 Omicron BA.1 spike protein. Participants aged ≥ 18 years previously vaccinated with ≥ 2 doses of an mRNA COVID-19 vaccine received CV0501 doses ranging from 12 to 200 μg. After assessment of safety and immunogenicity of the 12 μg dose in 30 adults, 30 adults ≤ 64 years were randomized to receive either a 3 or 6 μg dose. Solicited adverse events (AEs) were collected for 7 days, unsolicited AEs for 28 days, and serious AEs (SAEs), medically attended AEs (MAAEs), and AEs of special interest (AESIs) until day (D) 181 post-vaccination. Serum neutralizing titers specific to SARS-CoV-2 BA.1, wild-type, Delta, and additional Omicron subvariants were assessed at D1, D15, D29, D91, and D181. Of 180 vaccinated participants (mean age: 49.3 years; 57.8% women), 70.6% had prior SARS-CoV-2 infection. Most solicited local (98.1%) and systemic (96.7%) AEs were of mild-to-moderate severity; the most common were injection site pain (57.5%; 33.3-73.3% across groups) and myalgia (36.9%; 13.3-56.7%). Unsolicited AEs were reported by 14.4% (6.7-26.7%) of participants (mild-to-moderate severity in 88.5% of the participants). Three participants (1.7%) reported SAEs, 16.7% (6.7-30.0%) reported MAAEs, and 8.3% (0.0-13.3%) reported AESIs (15 COVID-19 cases), none related to vaccination. Geometric means of serum neutralizing titers increased from baseline to D15 and D29 (dose-dependent), and then decreased over time. The safety and immunogenicity results supported advancement to a phase 2 trial.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Essink</LastName><ForeName>Brandon J</ForeName><Initials>BJ</Initials><Identifier Source="ORCID">0000-0002-7309-228X</Identifier><AffiliationInfo><Affiliation>Velocity Clinical Research, Omaha, NE, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shapiro</LastName><ForeName>Craig</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>CenExel RCA, Hollywood, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Isidro</LastName><ForeName>Marie Grace Dawn</ForeName><Initials>MGD</Initials><Identifier Source="ORCID">0000-0002-8628-175X</Identifier><AffiliationInfo><Affiliation>West Visayas State University, Iloilo, Philippines.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bradley</LastName><ForeName>Paul</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Velocity Clinical Research, Savannah, GA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pragalos</LastName><ForeName>Antoinette</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>CTI Clinical Research Center, Cincinnati, OH, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bloch</LastName><ForeName>Mark</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-1143-5013</Identifier><AffiliationInfo><Affiliation>Holdsworth House Medical Practice Sydney, Darlinghurst, New South Wales, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Santiaguel</LastName><ForeName>Joel</ForeName><Initials>J</Initials><Identifier Source="ORCID">0009-0001-3951-0425</Identifier><AffiliationInfo><Affiliation>Quirino Memorial Medical Center, Quezon, Philippines.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>University of the Philippines College of Medicine, Manila, Philippines.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Frias</LastName><ForeName>Melchor Victor</ForeName><Initials>MV</Initials><Identifier Source="ORCID">0000-0003-3716-9419</Identifier><AffiliationInfo><Affiliation>De La Salle Medical and Health Sciences Institute, Dasmariñas, Cavite, Philippines.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miyakis</LastName><ForeName>Spiros</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0003-4268-1599</Identifier><AffiliationInfo><Affiliation>Wollongong Hospital, Wollongong, New South Wales, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Graduate School of Medicine, University of Wollongong, Wollongong, New South Wales, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alves de Mesquita</LastName><ForeName>Margarida</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>CureVac SE, Wiesbaden, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Berrè</LastName><ForeName>Stefano</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>GSK, Rixensart, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Servais</LastName><ForeName>Charlotte</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>GSK, Rixensart, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Waugh</LastName><ForeName>Natasha</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>GSK, Brentford, Middlesex, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hoffmann</LastName><ForeName>Claudia</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>CureVac SE, Wiesbaden, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Baba</LastName><ForeName>Emna</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>GSK, Wavre, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schönborn-Kellenberger</LastName><ForeName>Oliver</ForeName><Initials>O</Initials><Identifier Source="ORCID">0000-0002-5266-7881</Identifier><AffiliationInfo><Affiliation>CureVac SE, Wiesbaden, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wolz</LastName><ForeName>Olaf-Oliver</ForeName><Initials>OO</Initials><Identifier Source="ORCID">0000-0002-3140-7204</Identifier><AffiliationInfo><Affiliation>CureVac SE, Tübingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Koch</LastName><ForeName>Sven D</ForeName><Initials>SD</Initials><Identifier Source="ORCID">0000-0002-6178-0448</Identifier><AffiliationInfo><Affiliation>CureVac SE, Tübingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ganyani</LastName><ForeName>Tapiwa</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0002-9116-3117</Identifier><AffiliationInfo><Affiliation>GSK, Wavre, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boutet</LastName><ForeName>Philippe</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>GSK, Rixensart, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mann</LastName><ForeName>Philipp</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0001-8130-2032</Identifier><AffiliationInfo><Affiliation>CureVac SE, Wiesbaden, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mueller</LastName><ForeName>Stefan O</ForeName><Initials>SO</Initials><AffiliationInfo><Affiliation>CureVac SE, Tübingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ramanathan</LastName><ForeName>Roshan</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>GSK, Rockville, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gaudinski</LastName><ForeName>Martin Robert</ForeName><Initials>MR</Initials><Identifier Source="ORCID">0000-0002-3743-5281</Identifier><AffiliationInfo><Affiliation>GSK, Rockville, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vanhoutte</LastName><ForeName>Nicolas</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>GSK, Wavre, Belgium.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017426">Clinical Trial, Phase I</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>18</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Hum Vaccin Immunother</MedlineTA><NlmUniqueID>101572652</NlmUniqueID><ISSNLinking>2164-5515</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000086663">COVID-19 Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D057134">Antibodies, Neutralizing</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D064370">Spike Glycoprotein, Coronavirus</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014614">Vaccines, Synthetic</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000087503">mRNA Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008055">Lipids</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000657845">spike protein, SARS-CoV-2</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000711949">Lipid Nanoparticles</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000097007">Nanovaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008081">Liposomes</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086663" MajorTopicYN="Y">COVID-19 Vaccines</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057134" MajorTopicYN="Y">Antibodies, Neutralizing</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="Y">Antibodies, Viral</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053758" MajorTopicYN="Y">Nanoparticles</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000071497" MajorTopicYN="Y">Immunogenicity, Vaccine</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D064370" MajorTopicYN="Y">Spike Glycoprotein, Coronavirus</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014614" MajorTopicYN="N">Vaccines, Synthetic</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000087503" MajorTopicYN="N">mRNA Vaccines</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008055" MajorTopicYN="N">Lipids</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007117" MajorTopicYN="N">Immunization, Secondary</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000097007" MajorTopicYN="N">Nanovaccines</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008081" MajorTopicYN="N">Liposomes</DescriptorName></MeshHeading></MeshHeadingList><OtherAbstract Type="plain-language-summary" Language="eng"><AbstractText><b>What is the context?</b> Since 2019, more than 776 million people have been infected with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) worldwide, and more than 7 million people have died due to COVID-19.The virus changes over time and new variants may evade the protection provided by vaccines that are effective against previous variants.Therefore, it is necessary to develop vaccines that can be quickly updated to better protect against COVID-19 caused by new SARS-CoV-2 variants.We developed an mRNA vaccine, CV0501, that encodes a key protein on the surface of the SARS-CoV-2 Omicron BA.1 variant to instruct the immune system for future protection against COVID-19. The mRNA is encased in lipid nanoparticles that can increase the immune response to the vaccine.<b>What is new?</b> We administered different dose levels (that is, different amounts of mRNA) of CV0501 to adults who had previously been vaccinated at least twice with a different COVID-19 vaccine.We found that even at increased dose levels, CV0501 caused mostly mild side effects that resolved within a few days. Serious adverse events or events that required medical attention were not related to the vaccine.We also found that CV0501 generated immune responses not only against the Omicron BA.1 subvariant (vaccine antigen) but also against the original SARS-CoV-2 variant, the Delta variant, and other Omicron subvariants, at all dose levels tested.<b>What is the impact?</b> Our findings indicate that the CV0501 vaccine was well tolerated and induced immune responses against vaccine target variant as well as other SARS-CoV-2 variants.Other vaccines against COVID-19 based on the mRNA technology used for CV0501 will be further evaluated.</AbstractText></OtherAbstract><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2 variants</Keyword><Keyword MajorTopicYN="N">booster</Keyword><Keyword MajorTopicYN="N">clinical trial</Keyword><Keyword MajorTopicYN="N">immunogenicity</Keyword><Keyword MajorTopicYN="N">mRNA vaccine</Keyword><Keyword MajorTopicYN="N">safety</Keyword></KeywordList><CoiStatement>MAM, CHo, SDK, PM, OOW, and SOM are employees of CureVac. MAM, SDK, PM, and SOM hold shares in CureVac. CHo and OSK received consulting fees from CureVac. PM declares CureVac patents. SB, CSe, NW, EB, TG, PBo, RR, MG, and NV are employees of GSK. CSe, EB, PBo, MG, RR, and NV hold financial equitiesshares in GSK as part of their employee remunerations. MB reports institutional research grants from MSD, ViiV Healthcare, GSK, Gilead Sciences, AbbVie, Novavax, Sanofi, Eli Lilly, Novo Nordisk, EyeGene, Cymra Life Sciences, and personal honoraria for lectures from ViiV Healthcare and Gilead Sciences; for attending educational meetings from ViiV Healthcare and Gilead Sciences; for Advisory Board participation from ViiV Healthcare and Gilead Sciences, and Data Safety Monitoring Board participation from Cymra Life Sciences and EyeGene; and for his role in the New South Wales Ministerial HIV implementation Committee. MVF reports institutional research grants from GSK for the running of the clinical trial. SM reports consulting fees from Novartis and personal honoraria for lectures from Gilead Sciences, for support for attending meetings and/or travel from Pfizer, and for participation in an Advisory Board or Data Safety Monitoring Board from MSD. BJE, CSh, MGDI, PBr, AP, and JS have no conflicts of interest. The authors declare no other financial or non-financial relationships or activities.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>18</Day><Hour>16</Hour><Minute>21</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>18</Day><Hour>16</Hour><Minute>20</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>18</Day><Hour>7</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>10</Month><Day>18</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39422261</ArticleId><ArticleId IdType="pmc">PMC11492660</ArticleId><ArticleId IdType="doi">10.1080/21645515.2024.2408863</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>World Health Organization . WHO Coronavirus (COVID-19) Dashboard. 2024.  [accessed 2024 Sep
3]. http://covid19.who.int/table.</Citation></Reference><Reference><Citation>Tosta S, Moreno K, Schuab G, Fonseca V, Segovia FMC, Kashima S, Elias MC, Sampaio SC, Ciccozzi M, Alcantara LCJ, et al. Global SARS-CoV-2 genomic surveillance: what we have learned (so far). Infect Genet Evol. 2023;108:105405. doi:10.1016/j.meegid.2023.105405.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.meegid.2023.105405</ArticleId><ArticleId IdType="pmc">PMC9847326</ArticleId><ArticleId IdType="pubmed">36681102</ArticleId></ArticleIdList></Reference><Reference><Citation>Markov PV, Ghafari M, Beer M, Lythgoe K, Simmonds P, Stilianakis NI, Katzourakis A.. The evolution of SARS-CoV-2. Nat Rev Microbiol. 2023;21(6):361–15. doi:10.1038/s41579-023-00878-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41579-023-00878-2</ArticleId><ArticleId IdType="pubmed">37020110</ArticleId></ArticleIdList></Reference><Reference><Citation>Szabó GT, Mahiny AJ, Vlatkovic I. COVID-19 mRNA vaccines: platforms and current developments. Mol Ther. 2022;30(5):1850–1868. doi:10.1016/j.ymthe.2022.02.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ymthe.2022.02.016</ArticleId><ArticleId IdType="pmc">PMC8856755</ArticleId><ArticleId IdType="pubmed">35189345</ArticleId></ArticleIdList></Reference><Reference><Citation>Hogan MJ, Pardi N. mRNA vaccines in the COVID-19 pandemic and beyond. Annu Rev Med. 2022;73(1):17–39. doi:10.1146/annurev-med-042420-112725.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev-med-042420-112725</ArticleId><ArticleId IdType="pubmed">34669432</ArticleId></ArticleIdList></Reference><Reference><Citation>Menni C, May A, Polidori L, Louca P, Wolf J, Capdevila J, Hu C, Ourselin S, Steves CJ, Valdes AM, et al. COVID-19 vaccine waning and effectiveness and side-effects of boosters: a prospective community study from the ZOE COVID study. Lancet Infect Dis. 2022;22(7):1002–1010. doi:10.1016/s1473-3099(22)00146-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s1473-3099(22)00146-3</ArticleId><ArticleId IdType="pmc">PMC8993156</ArticleId><ArticleId IdType="pubmed">35405090</ArticleId></ArticleIdList></Reference><Reference><Citation>Paternina-Caicedo A, Quevedo DS, Ríos DS, Moyano D, Alvis-Guzmán N, Alviz-Zakzuk NR, Salcedo F, Moyano L, Ramírez-Suarez J, Smith AD, et al. Comparative effectiveness and duration of protection of ChAdOx1, CoronaVac, BNT162b2, mRNA-1273, and Ad26.COV2.S COVID-19 vaccines for symptomatic and hospitalized mu, delta, and omicron: a test-negative case-control study. Vaccine. 2023;41(42):6291–6299. doi:10.1016/j.vaccine.2023.08.072.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2023.08.072</ArticleId><ArticleId IdType="pubmed">37679278</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferdinands JM, Rao S, Dixon BE, Mitchell PK, DeSilva MB, Irving SA, Lewis N, Natarajan K, Stenehjem E, Grannis SJ, et al. Waning 2-dose and 3-dose effectiveness of mRNA vaccines against COVID-19-Associated emergency department and urgent care encounters and hospitalizations among adults during periods of delta and omicron variant predominance - VISION network, 10 States, August 2021-January 2022. MMWR Morb Mortal Wkly Rep. 2022;71(7):255–263. doi:10.15585/mmwr.mm7107e2.</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm7107e2</ArticleId><ArticleId IdType="pmc">PMC8853475</ArticleId><ArticleId IdType="pubmed">35176007</ArticleId></ArticleIdList></Reference><Reference><Citation>Tseng HF, Ackerson BK, Bruxvoort KJ, Sy LS, Tubert JE, Lee GS, Ku JH, Florea A, Luo Y, Qiu S, et al. Effectiveness of mRNA-1273 vaccination against SARS-CoV-2 omicron subvariants BA.1, BA.2, BA.2.12.1, BA.4, and BA.5. Nat Commun. 2023;14(1):189. doi:10.1038/s41467-023-35815-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-023-35815-7</ArticleId><ArticleId IdType="pmc">PMC9836332</ArticleId><ArticleId IdType="pubmed">36635284</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Q, Iketani S, Li Z, Liu L, Guo Y, Huang Y, Bowen AD, Liu M, Wang M, Yu J, et al. Alarming antibody evasion properties of rising SARS-CoV-2 BQ and XBB subvariants. Cell. 2023;186(2):279–86.e278. doi:10.1016/j.cell.2022.12.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2022.12.018</ArticleId><ArticleId IdType="pmc">PMC9747694</ArticleId><ArticleId IdType="pubmed">36580913</ArticleId></ArticleIdList></Reference><Reference><Citation>Brüssow H. COVID-19: omicron – the latest, the least virulent, but probably not the last variant of concern of SARS-CoV-2. Microb Biotechnol. 2022;15(7):1927–1939. doi:10.1111/1751-7915.14064.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/1751-7915.14064</ArticleId><ArticleId IdType="pmc">PMC9111164</ArticleId><ArticleId IdType="pubmed">35443078</ArticleId></ArticleIdList></Reference><Reference><Citation>Pascall DJ, Vink E, Blacow R, Bulteel N, Campbell A, Campbell R, Clifford S, Davis C, da Silva Filipe A, El Sakka N, et al. Directions of change in intrinsic case severity across successive SARS-CoV-2 variant waves have been inconsistent. J Infect. 2023;87(2):128–135. doi:10.1016/j.jinf.2023.05.019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jinf.2023.05.019</ArticleId><ArticleId IdType="pmc">PMC10234362</ArticleId><ArticleId IdType="pubmed">37270070</ArticleId></ArticleIdList></Reference><Reference><Citation>Uraki R, Ito M, Furusawa Y, Yamayoshi S, Iwatsuki-Horimoto K, Adachi E, Saito M, Koga M, Tsutsumi T, Yamamoto S, et al. Humoral immune evasion of the omicron subvariants BQ.1.1 and XBB. Lancet Infect Dis. 2023;23(1):30–32. doi:10.1016/s1473-3099(22)00816-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s1473-3099(22)00816-7</ArticleId><ArticleId IdType="pmc">PMC9729000</ArticleId><ArticleId IdType="pubmed">36495917</ArticleId></ArticleIdList></Reference><Reference><Citation>Qu P, Faraone JN, Evans JP, Zheng YM, Carlin C, Anghelina M, Stevens P, Fernandez S, Jones D, Panchal AR, et al. Enhanced evasion of neutralizing antibody response by Omicron XBB.1.5, CH.1.1, and CA.3.1 variants. Cell Rep. 2023;42(5):112443. doi:10.1016/j.celrep.2023.112443.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2023.112443</ArticleId><ArticleId IdType="pmc">PMC10279473</ArticleId><ArticleId IdType="pubmed">37104089</ArticleId></ArticleIdList></Reference><Reference><Citation>Centers for Disease Control and Prevention . Stay up to date with COVID-19 vaccines. 2023.  [accessed 2023 Dec
5]. https://www.cdc.gov/coronavirus/2019-ncov/vaccines/stay-up-to-date.html#UTD.</Citation></Reference><Reference><Citation>Comission E . COVID-19: commission authorises adapted COVID-19 vaccine for member states’ autumn vaccination campaigns. 2023.  [accessed 2023 Dec
5]. https://ec.europa.eu/commission/presscorner/detail/en/ip_23_4301.</Citation></Reference><Reference><Citation>World Health Organization . Statement on the antigen composition of COVID-19 vaccines, 13 December 2023. 2023.  [accessed 2024 Feb
5]. https://www.who.int/news/item/13-12-2023-statement-on-the-antigen-composition-of-covid-19-vaccines.</Citation></Reference><Reference><Citation>Kremsner PG, Ahuad Guerrero RA, Arana-Arri E, Aroca Martinez GJ, Bonten M, Chandler R, Corral G, De Block EJL, Ecker L, Gabor JJ, et al. Efficacy and safety of the CVnCoV SARS-CoV-2 mRNA vaccine candidate in ten countries in Europe and Latin America (HERALD): a randomised, observer-blinded, placebo-controlled, phase 2b/3 trial. Lancet Infect Dis. 2022;22(3):329–340. doi:10.1016/s1473-3099(21)00677-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s1473-3099(21)00677-0</ArticleId><ArticleId IdType="pmc">PMC8610426</ArticleId><ArticleId IdType="pubmed">34826381</ArticleId></ArticleIdList></Reference><Reference><Citation>Alameh MG, Tombácz I, Bettini E, Lederer K, Sittplangkoon C, Wilmore JR, Gaudette BT, Soliman OY, Pine M, Hicks P, et al. Lipid nanoparticles enhance the efficacy of mRNA and protein subunit vaccines by inducing robust T follicular helper cell and humoral responses. Immunity. 2021;54(12):2877–92.e7. doi:10.1016/j.immuni.2021.11.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2021.11.001</ArticleId><ArticleId IdType="pmc">PMC8566475</ArticleId><ArticleId IdType="pubmed">34852217</ArticleId></ArticleIdList></Reference><Reference><Citation>Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, Diemert D, Spector SA, Rouphael N, Creech CB, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med. 2021;384(5):403–416. doi:10.1056/NEJMoa2035389.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2035389</ArticleId><ArticleId IdType="pmc">PMC7787219</ArticleId><ArticleId IdType="pubmed">33378609</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma Q, Li M, Ma L, Zhang C, Zhang H, Zhong H, Wen J, Wang Y, Yan Z, Xiong W, et al. SARS-CoV-2 bivalent mRNA vaccine with broad protection against variants of concern. Front Immunol. 2023;14:1195299. doi:10.3389/fimmu.2023.1195299.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2023.1195299</ArticleId><ArticleId IdType="pmc">PMC10244545</ArticleId><ArticleId IdType="pubmed">37292197</ArticleId></ArticleIdList></Reference><Reference><Citation>Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, Perez JL, Pérez Marc G, Moreira ED, Zerbini C, et al. Safety and efficacy of the BNT162b2 mRNA covid-19 vaccine. N Engl J Med. 2020;383(27):2603–2615. doi:10.1056/NEJMoa2034577.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2034577</ArticleId><ArticleId IdType="pmc">PMC7745181</ArticleId><ArticleId IdType="pubmed">33301246</ArticleId></ArticleIdList></Reference><Reference><Citation>Al Fayez N, Nassar MS, Alshehri AA, Alnefaie MK, Almughem FA, Alshehri BY, Alawad AO, Tawfik EA. Recent advancement in mRNA vaccine development and applications. Pharmaceutics. 2023;15(7):1972. doi:10.3390/pharmaceutics15071972.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/pharmaceutics15071972</ArticleId><ArticleId IdType="pmc">PMC10384963</ArticleId><ArticleId IdType="pubmed">37514158</ArticleId></ArticleIdList></Reference><Reference><Citation>Gebre MS, Rauch S, Roth N, Yu J, Chandrashekar A, Mercado NB, He X, Liu J, McMahan K, Martinot A, et al. Optimization of non-coding regions for a non-modified mRNA COVID-19 vaccine. Nature. 2022;601(7893):410–414. doi:10.1038/s41586-021-04231-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-04231-6</ArticleId><ArticleId IdType="pmc">PMC8770133</ArticleId><ArticleId IdType="pubmed">34794169</ArticleId></ArticleIdList></Reference><Reference><Citation>Roth N, Gergen J, Kovacikova K, Mueller SO, Ulrich L, Schön J, Halwe NJ, Fricke C, Corleis B, Dorhoi A, et al. Assessment of immunogenicity and efficacy of CV0501 mRNA-based omicron COVID-19 vaccination in small animal models. Vaccines (Basel). 2023;11(2):318. doi:10.3390/vaccines11020318.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines11020318</ArticleId><ArticleId IdType="pmc">PMC9965737</ArticleId><ArticleId IdType="pubmed">36851196</ArticleId></ArticleIdList></Reference><Reference><Citation>Bewley KR, Coombes NS, Gagnon L, McInroy L, Baker N, Shaik I, St-Jean JR, St-Amant N, Buttigieg KR, Humphries HE, et al. Quantification of SARS-CoV-2 neutralizing antibody by wild-type plaque reduction neutralization, microneutralization and pseudotyped virus neutralization assays. Nat Protoc. 2021;16(6):3114–3140. doi:10.1038/s41596-021-00536-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41596-021-00536-y</ArticleId><ArticleId IdType="pubmed">33893470</ArticleId></ArticleIdList></Reference><Reference><Citation>Leroux-Roels I, Davis MG, Steenackers K, Essink B, Vandermeulen C, Fogarty C, Andrews CP, Kerwin E, David MP, Fissette L, et al. Safety and immunogenicity of a respiratory syncytial virus prefusion F (RSVPreF3) candidate vaccine in older adults: phase 1/2 randomized clinical trial. J Infect Dis. 2023;227(6):761–772. doi:10.1093/infdis/jiac327.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiac327</ArticleId><ArticleId IdType="pmc">PMC10044090</ArticleId><ArticleId IdType="pubmed">35904987</ArticleId></ArticleIdList></Reference><Reference><Citation>Moris P, van der Most R, Leroux-Roels I, Clement F, Dramé M, Hanon E, Leroux-Roels GG, Van Mechelen M. H5N1 influenza vaccine formulated with AS03 a induces strong cross-reactive and polyfunctional CD4 T-cell responses. J Clin Immunol. 2011;31(3):443–454. doi:10.1007/s10875-010-9490-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10875-010-9490-6</ArticleId><ArticleId IdType="pmc">PMC3132412</ArticleId><ArticleId IdType="pubmed">21174144</ArticleId></ArticleIdList></Reference><Reference><Citation>Chapin-Bardales J, Gee J, Myers T. Reactogenicity following receipt of mRNA-based COVID-19 vaccines. JAMA. 2021;325(21):2201–2202. doi:10.1001/jama.2021.5374.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2021.5374</ArticleId><ArticleId IdType="pubmed">33818592</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee IT, Cosgrove CA, Moore P, Bethune C, Nally R, Bula M, Kalra PA, Clark R, Dargan PI, Boffito M, et al. Omicron BA.1-containing mRNA-1273 boosters compared with the original COVID-19 vaccine in the UK: a randomised, observer-blind, active-controlled trial. Lancet Infect Dis. 2023;23(9):1007–1019. doi:10.1016/s1473-3099(23)00295-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s1473-3099(23)00295-5</ArticleId><ArticleId IdType="pubmed">37348519</ArticleId></ArticleIdList></Reference><Reference><Citation>Walsh EE, Frenck RW Jr., Falsey AR, Kitchin N, Absalon J, Gurtman A, Lockhart S, Neuzil K, Mulligan MJ, Bailey R, et al. Safety and immunogenicity of two RNA-Based covid-19 vaccine candidates. N Engl J Med. 2020;383(25):2439–2450. doi:10.1056/NEJMoa2027906.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2027906</ArticleId><ArticleId IdType="pmc">PMC7583697</ArticleId><ArticleId IdType="pubmed">33053279</ArticleId></ArticleIdList></Reference><Reference><Citation>Munro APS, Feng S, Janani L, Cornelius V, Aley PK, Babbage G, Baxter D, Bula M, Cathie K, Chatterjee K, et al. Safety, immunogenicity, and reactogenicity of BNT162b2 and mRNA-1273 COVID-19 vaccines given as fourth-dose boosters following two doses of ChAdOx1 nCoV-19 or BNT162b2 and a third dose of BNT162b2 (COV-BOOST): a multicentre, blinded, phase 2, randomised trial. Lancet Infect Dis. 2022;22(8):1131–1141. doi:10.1016/s1473-3099(22)00271-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s1473-3099(22)00271-7</ArticleId><ArticleId IdType="pmc">PMC9084623</ArticleId><ArticleId IdType="pubmed">35550261</ArticleId></ArticleIdList></Reference><Reference><Citation>Munro APS, Janani L, Cornelius V, Aley PK, Babbage G, Baxter D, Bula M, Cathie K, Chatterjee K, Dodd K, et al. Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial. The Lancet. 2021;398(10318):2258–2276. doi:10.1016/s0140-6736(21)02717-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0140-6736(21)02717-3</ArticleId><ArticleId IdType="pmc">PMC8639161</ArticleId><ArticleId IdType="pubmed">34863358</ArticleId></ArticleIdList></Reference><Reference><Citation>Kremsner PG, Mann P, Kroidl A, Leroux-Roels I, Schindler C, Gabor JJ, Schunk M, Leroux-Roels G, Bosch JJ, Fendel R, et al. Safety and immunogenicity of an mRNA-lipid nanoparticle vaccine candidate against SARS-CoV-2: a phase 1 randomized clinical trial. Wien Klin Wochenschr. 2021;133(17–18):931–941. doi:10.1007/s00508-021-01922-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00508-021-01922-y</ArticleId><ArticleId IdType="pmc">PMC8354521</ArticleId><ArticleId IdType="pubmed">34378087</ArticleId></ArticleIdList></Reference><Reference><Citation>Dan JM, Mateus J, Kato Y, Hastie KM, Yu ED, Faliti CE, Grifoni A, Ramirez SI, Haupt S, Frazier A, et al. Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection. Science. 2021;371(6529):eabf4063. doi:10.1126/science.abf4063.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abf4063</ArticleId><ArticleId IdType="pmc">PMC7919858</ArticleId><ArticleId IdType="pubmed">33408181</ArticleId></ArticleIdList></Reference><Reference><Citation>Grifoni A, Weiskopf D, Ramirez SI, Mateus J, Dan JM, Moderbacher CR, Rawlings SA, Sutherland A, Premkumar L, Jadi RS, et al. Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals. Cell. 2020;181(7):1489–501.e1415. doi:10.1016/j.cell.2020.05.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.05.015</ArticleId><ArticleId IdType="pmc">PMC7237901</ArticleId><ArticleId IdType="pubmed">32473127</ArticleId></ArticleIdList></Reference><Reference><Citation>Arunachalam PS, Lai L, Samaha H, Feng Y, Hu M, Hui H-Y, Wali B, Ellis M, Davis-Gardner ME, Huerta C, et al. Durability of immune responses to mRNA booster vaccination against COVID-19. J Clin Invest. 2023;133(10):e167955. doi:10.1172/JCI167955.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI167955</ArticleId><ArticleId IdType="pmc">PMC10178835</ArticleId><ArticleId IdType="pubmed">36951954</ArticleId></ArticleIdList></Reference><Reference><Citation>Saville M. COVID-19: release approved vaccines for trials of new ones. Nature. 2021;597(7875):178. doi:10.1038/d41586-021-02398-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/d41586-021-02398-6</ArticleId><ArticleId IdType="pubmed">34493842</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>